Literature DB >> 31155469

Comparing the influence of 2009 versus 2016 ASE/EACVI diastolic function guidelines on the prevalence and echocardiographic characteristics of preclinical diastolic dysfunction (stage B heart failure) in a Hispanic population with type 2 diabetes mellitus.

Siu-Hin Wan1, Andrew S Pumerantz2, Fanglong Dong3, Cesar Ochoa4, Horng H Chen5.   

Abstract

AIMS: To identify prevalence and predictors of undetected pre-clinical diastolic dysfunction (PDD) in a cohort of adult Hispanic patients with type 2 diabetes (T2D), and compare variations in epidemiology and echocardiographic characteristics between categorization based on the 2009 versus 2016 guidelines.
METHODS: From 2013 to 2016, a cross-sectional cohort study of adults with T2D was performed. Patients without signs/symptoms of heart failure (HF) underwent 2D/Doppler echocardiographic screening, and were grouped into two subcohorts: 1) normal diastolic function, and 2) PDD, defined by the 2009 or 2016 ASE/EACVI criteria.
RESULTS: Among 307 Hispanic subjects, by 2009 criteria, 193 (62.9%) had normal diastolic function, 113 (36.8%) diastolic dysfunction and 1 (0.3%) indeterminate. Those that had diastolic dysfunction (DD) were older (mean age 59.1 ± 12.7 vs 52.2 ± 12.2 years, p< 0.0001), with higher proportion female (69.0 vs 53.9%, p = 0.0092), and higher systolic blood pressure (136.5 ± 18.6 vs 131.7 ± 19.9, p = 0.0372). By 2016 criteria, 261 (85%) had normal diastolic function, 22 (7.2%) diastolic dysfunction and 24 (7.8%) indeterminate. Among those that had normal diastolic function (n = 261) by 2016 criteria, 29% (n = 76) had DD by 2009 criteria, and they were more likely to have higher E/e' and left atrial volume index (LAVI).
CONCLUSIONS: By applying the 2016 versus the 2009 diastolic function criteria to a Hispanic population with T2D, the prevalence of PDD decreased significantly from 37% to 7%. These findings are consistent with recent studies demonstrating that the 2016 ASE/EACVI guidelines are more specific for diagnosing DD and hence less sensitive leading to lower prevalence of diastolic dysfunction.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Echocardiography; Epidemiology; Heart failure; Hispanic; Pre-clinical diastolic dysfunction; Type 2 diabetes

Year:  2019        PMID: 31155469      PMCID: PMC6830437          DOI: 10.1016/j.jdiacomp.2019.04.015

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  33 in total

1.  Race/ethnic disparities in left ventricular diastolic function in a triethnic community cohort.

Authors:  Cesare Russo; Zhezhen Jin; Shunichi Homma; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco; Marco R Di Tullio
Journal:  Am Heart J       Date:  2010-07       Impact factor: 4.749

2.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner
Journal:  J Am Soc Echocardiogr       Date:  2016-04       Impact factor: 5.251

3.  Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study.

Authors:  Mark T Ledwidge; Eoin O'Connell; Joseph Gallagher; Lesley Tilson; Stephanie James; Victor Voon; Margaret Bermingham; Elaine Tallon; Chris Watson; Rory O'Hanlon; Michael Barry; Kenneth McDonald
Journal:  Eur J Heart Fail       Date:  2015-07       Impact factor: 15.534

4.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

Authors:  Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald
Journal:  JAMA       Date:  2013-07-03       Impact factor: 56.272

5.  Impact of diabetes on cardiac structure and function: the strong heart study.

Authors:  R B Devereux; M J Roman; M Paranicas; M J O'Grady; E T Lee; T K Welty; R R Fabsitz; D Robbins; E R Rhoades; B V Howard
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

6.  The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study.

Authors:  Christian Bommer; Esther Heesemann; Vera Sagalova; Jennifer Manne-Goehler; Rifat Atun; Till Bärnighausen; Sebastian Vollmer
Journal:  Lancet Diabetes Endocrinol       Date:  2017-04-26       Impact factor: 32.069

7.  The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota.

Authors:  Sanjay Dandamudi; Joshua Slusser; Douglas W Mahoney; Margaret M Redfield; Richard J Rodeheffer; Horng H Chen
Journal:  J Card Fail       Date:  2014-02-24       Impact factor: 5.712

8.  Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter?

Authors:  Teresa S M Tsang; Walter P Abhayaratna; Marion E Barnes; Yoko Miyasaka; Bernard J Gersh; Kent R Bailey; Stephen S Cha; James B Seward
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

Review 9.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.

Authors:  Cecilia C Low Wang; Connie N Hess; William R Hiatt; Allison B Goldfine
Journal:  Circulation       Date:  2016-06-14       Impact factor: 29.690

Review 10.  Diabetes: a 21st century challenge.

Authors:  Paul Z Zimmet; Dianna J Magliano; William H Herman; Jonathan E Shaw
Journal:  Lancet Diabetes Endocrinol       Date:  2013-12-03       Impact factor: 32.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.